RESEARCH ARTICLE

Identification of a Novel NLRP12 Nonsense Mutation (Trp408X) in the Extremely Rare Disease FCAS by Exome Sequencing

Xiaoru Xia¹, Caijun Dai², Xiaochun Zhu¹, Qiumei Liao¹, Xu Luo³, Yangyang Fu², Liangxing Wang²*

¹ Department of Rheumatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China, ² Department of Pneumology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China, ³ Department of Wounds and Burns, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China

* wzxywix@163.com

Abstract

Familial cold autoinflammatory syndrome (FCAS) is an extremely rare autosomal dominant inherited disease. Although there are four genes that have been linked with FCAS, its molecular diagnosis has been challenging in a relatively large proportion of cases. In this study, we aimed to investigate the genetic defect of a recruited FCAS family using exome sequencing followed by in-depth bioinformatics analysis. As a result, a novel heterozygous stop-gain mutation (Trp408X) in NLRP12 was identified in autosomal dominant inherited FCAS with clinical features of recurrent fever and skin urticaria due to cold conditions. When combined with previous studies, all of the reported mutations were found to have occurred in a highly conserved region in the NACHT domain coding sequence in NLRP12 exon 3, suggesting that a screening strategy for FCAS should focus on this area of the gene. In conclusion, this study demonstrates the importance of exome sequencing for clinical diagnosis of genetic disorders and provides molecular insight into FCAS treatment and diagnosis.

Introduction

Cryopyrin-associated periodic syndromes (CAPS) are rare prototypical hereditary autoinflammatory diseases with a prevalence of approximately 1 in 360,000 in France [1] and 1 in 1,000,000 in the USA [2]. According to clinical symptoms, CAPS can be divided into three different subtypes: familial cold autoinflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS), and chronic infantile neurological cutaneous articular syndrome/neonatal onset multisystem autoinflammatory syndrome (CINCA/NOMID). FCAS is the mildest type of CAPS disorder, in which exposure to cold temperatures results in recurrent systemic inflammation involving skin urticaria, recurrent fever and/or joint pain. These symptoms can last much longer in MWS (1–3 days) than in FCAS (12–24h). Sensorineural hearing loss and secondary
Amyloidosis can be observed in some MWS and CINCA/NOMID patients. In addition to cutaneous involvement, bone deformities, progressive vision loss and central nervous system manifestations, such as aseptic meningitis, can also appear in CINCA/NOMID [3].

The heterogeneity of clinical symptoms suggests that different genes may be responsible for different phenotypes. It is known that FCAS displays autosomal dominant inheritance [4]. Mutations in four genes—NLRP3, NLRC4, NLRP12 and PLCG2—have been linked to FCAS [5–8]. For example, a number of NLRP3 mutations have been associated with adult-onset FCAS. Specifically, p.Leu353Pro and p.Leu305Pro in NLRP3 result in the development of FCAS [9, 10], while the mutations p.Phe309Ser and p.Tyr570Cys tend to result in more severe phenotypes such as neurological disorders [11]. Mutations in PLCG2 are found in most patients with characteristic cutaneous manifestations [12]. Additionally, a group of patients who exhibit extreme sensitivity to cold were reported to carry the p.D294E mutation in NLRP12 [13]. However, the genotype-phenotype correlations are still not fully clear due to a limited number of reports on FCAS genetics. At present, the existence of additional genes underlying FCAS is unclear. More detailed knowledge would be helpful for early diagnosis and the development of therapeutic strategies for targeting the mutated gene.

In this study, we aimed to identify the genetic defects in a family diagnosed with FCAS and were especially interested in novel and previously identified disease genes. Exome sequencing is a highly versatile and effective approach for the detection of novel disease-causing genes and mutations. Thus, in this study, we applied exome sequencing to genetic mutation detection in one family affected by FCAS. As a result, a novel probable disease-causing mutation (p.Trp408X) in NLRP12 was identified in one family affected by autosomal-dominant FCAS, which provided molecular insight into FCAS treatment and diagnosis.

**Materials and Methods**

**Patient recruitment**

This study conformed to the guidelines of the Declaration of Helsinki and was approved by the Ethics Committee of the First Affiliated Hospital, Wenzhou Medical University. Written informed consent was obtained from all participating patients or their guardians. All of the patients were clinically evaluated by physicians experienced in FCAS diagnosis. Proposed diagnostic criteria for FCAS in these patients suggested an autosomal dominant inheritance pattern. The classical symptoms are recurrent episodes of rash and fever that can be induced by exposure to natural or experimental cold conditions. Symptoms begin during childhood and do not become worse during the patient’s lifetime. The duration of most attacks is less than 24h. Arthralgia and conjunctivitis combined with rash and fever occur in most patients. Deafness, periorbital edema, lymphadenopathy, and serositis are rare in FCAS.

**Sample preparation**

A total of 5 ml of peripheral blood were drawn from each patient and control (unaffected family members); the blood was collected in EDTA tubes and stored at -80°C. The individuals described in this study provided written informed consent for publication of case details (as outlined in the PLOS consent form). Genomic DNA was extracted from 1 ml of each blood sample using the DNeasy Blood and Tissue Kit (Qiagen, Germany). DNA quality and quantity were determined using a Nano drop 2000 spectrophotometer (Thermo Scientific). All DNA samples had OD260/OD280 values of 1.7–2.0 and were not degraded as determined by gel electrophoresis. The sample concentration was ≥50 ng/μl, and for most patients, the quantity was higher than 6 μg. Total DNA was stored at -80°C until use.
Exome sequencing
For each DNA sample to be sequenced, a single library was prepared using 3 μg of high molecular weight genomic DNA as the starting material using the Agilent SureSelect Library Prep kit. Exome capture was performed using an Agilent SureSelect Human All Exon kit. The samples were then tagged by PCR with different index (barcode) sequences. After assessing the quality and quantity of each library and pooling indexed samples, multiplex sequencing was performed using an Illumina HiSeq 2000 as a 100+100bp paired-end run. We have deposited the raw data on the Figshare (https://dx.doi.org/10.6084/m9.figshare.3406516.v9; DOI: 10.6084/m9.figshare.3406516).

Identification and annotation of SNPs and InDels
To identify genetic variants, we excluded 3'/5' adapters using Cutadapt implemented in Trim Galore software, and low quality reads were filtered for quality control. Only the reads in which the Phred-scaled sequencing quality was greater than 30 and the read length was greater than 80 bp were used. Each read was mapped to the human reference genome (hg19) using the Burrows-Wheeler Aligner (BWA) program. The GATK (Genome Analysis Toolkit) package was used for InDel realignment, recalibration and variant detection. Duplicated reads were removed using Sequence Alignment/Map tools (SAMtools), and only uniquely mapping reads were used for variation detection. SNP/InDels detected in all affected individuals and absent from unaffected family controls were retained. Detected sequence variants present in the dbSNP, 1000 Genome, ExAC, ESP 6500 and in an in-house Chinese Exome Database (1,500 Chinese Han individuals) were removed. SNVs predicted as deleterious by SIFT (http://sift.bii.a-star.edu.sg/), PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/), and Mutation Taster (www.mutationtaster.org/) programs were used. Annotation of the variants, such as locations (exonic, intronic, intergenic, etc.) and effects on protein coding sequences (synonymous, missense, nonsense, frameshift, etc.), was performed using an in-house bioinformatics tool with RefSeq (http://www.ncbi.nlm.nih.gov/refseq/) and UCSC gene annotations (hg19, from UCSC).

A total of 100 ng of genomic DNA from each sample was used to validate potential causative genes by conventional PCR and Sanger sequencing. Primers for the detected potential disease-causing mutation Trp408Xin NLRP12 were 5'-CCTGGAAACTCAAGTGGATG-3' (forward) and 5'-TGAGGCAGAAAGGAAGGAATA-3' (reverse).

Protein structural modeling
The tertiary structures of human wild-type and mutant NLRP12 were predicted using Rosetta software (https://www.rosettacommons.org/), and the results were saved as a PDB file format. The PDB files obtained for the two samples were then used by PyMOL (http://pymol.org/) to visualize the structures of these proteins.

Results
Characteristics of the patient cohort
The patient cohort for this study was a family composed of 18 individuals, as shown in Fig 1A. Based on the pedigrees, the inheritance pattern of the FCAS family in this study was most likely autosomal dominant. None of the patients had a history of asthma and all experienced urticarial rashes during childhood before 1 year of age (Fig 1B). The symptomatic periods in these patients were short and lasted for 12–24 h, and appeared 1 or 2 h after exposure to cold conditions. The urticarial-like rashes appeared on the limbs and the trunk and were sometimes
accompanied by fever, with most patients experiencing joint pain. These symptoms disappeared without treatment in this affected family. Hearing loss, mental retardation and renal disturbance were not observed in any of the affected individuals in this family, nor was there any incidence of systemic disorders. The clinical data are summarized in Table 1. A cold-induced dermatographism test result was negative. Elevated erythrocyte sedimentation rates and C-reactive protein levels were observed in all four living patients. Patients tested negative for autoantibodies. Based on these clinical manifestations, the most probable diagnosis in this family was FCAS.

**Mutation analysis**

Due to rapidly decreasing costs, exome sequencing has been increasingly applied as a powerful clinical diagnostic tool [14]. It can rapidly provide information that can be used for guidance...
and evidence relating to the causes of many diseases. In our study, to identify potential causative mutations for FCAS, we utilized whole exome sequencing (WES) to analyze three affected individuals (II-4, III-3 and IV-2) and three unaffected family members (II-5, III-4 and IV-1) of one family diagnosed with FCAS (Fig 2A). Here, we adopted similar strategies to those used in other published works for WES sequencing data processing and analysis [15–17]. After removing the 3’ and 5’ adapters using Cutadapt and the poor quality reads by FastQC, an average of 5.90 Gb of clean data remained per exome (Table 2). Next, we used BWA to map these clean reads to the human reference genome (hg19), allowing two mismatches per read. Overall, 99.13% of the reads were aligned to the reference genome. Among these mapped reads, approximately 55.33% were located in target regions with a mean of 59.48x sequencing depth. We observed that 96.03%, 92.37% and 83.43% of the sites in the target regions had greater than 4x, 10x and 20x read coverage, respectively. Above all, these data fully reflect the reliability of our sequencing data and provide a strong basis for follow-up analysis.

Using GATK, we identified 10,898 coding single nucleotide variants (SNVs, in this case, consisting of missense, stop-loss, stop-gain and splice site mutations) and 663 short coding insertions or deletions (InDels) by sequencing three patients in total (Fig 2B, Table 2). According to the autosomal dominant inheritance pattern, we assumed that the pathogenic cause of the disease in this family was due to the same heterozygous mutation in one gene. Therefore, we excluded the variants that were not shared in all affected individuals. After this exclusion, 3,212 SNVs and 107 InDels remained. To identify the causative mutation, the variants present in three normal family members were filtered, following which, the shared SNVs and InDels were reduced to 151 and 57, respectively. Then, we excluded the variants in common databases of normal controls, including dbSNP v138 (http://www.ncbi.nlm.nih.gov/projects/SNP/), 1000 Genomes (http://
Novel Mutation of NLRP12 in FCAS

www.1000genomes.org/), ExAC (http://exac.broadinstitute.org/), ESP6500 (http://evs.gs.washington.edu/EVS/) and our 1,500 Chinese in-house exome data sequenced by Beijing Genomics Institute, Shenzhen, China.

The number of remaining SNVs and InDels were 13 and 2 (S1 Table), respectively. These mutations were further analyzed with computational tools to predict their damaging effects. InDels were considered pathogenic if they caused a frameshift. For the nonsynonymous SNV mutations, we predicted the damaging effect using three tools [18], including PolyPhen-2, SIFT and Mutation Taster. After this step, two potentially damaging SNVs remained. We then performed a more comprehensive analysis of gene function, gene expression and intersection with known Mendelian disease loci. In addition, we reviewed these genes in the context of relevant literature about this disease. Finally, we identified a previously unreported heterozygous stop-gain mutation (Trp408X) in NLRP12. The other candidate mutation (PERM1, c.G1661A, p.R554Q) was not followed up because it was functionally unrelated to FCAS.

We conducted PCR and Sanger sequencing on all six family members and confirmed the heterozygous stop-gain (nonsense) mutation in the three affected subjects but not in the normal subjects (Fig 2C). Subsequently, we performed PCR and Sanger sequencing on the other members (all normal subjects) of the pedigree with available DNA samples and confirmed that they did not have the Trp408X mutation in NLRP12. This finding demonstrates the practical applicability of WES.

Protein structural modeling

The NLRP12 protein (http://www.uniprot.org/uniprot/P59046, ENSP00000319377) consists of an N-terminal DAPIN domain, a NACHT domain and C-terminal LRR (leucine-rich) repeats. The DAPIN/Pyrin domain is located between amino acids 1–95, and the NACHT domain is located at residues 211–528, with the remaining part of NLRP12 comprising the C-terminal LRRs (828–1,049). Using Rosetta software (https://www.rosettacommons.org/software), we predicted the 3D structure of the wild-type NLRP12 protein (1–1049) and mapped out the Trp408 residue in the structure (Fig 3). The p.Trp408X mutation results in a protein product with a deletion of the entire C-terminal LRR region and partial deletion of the NACHT domain. This nonsense mutation at this key region may lead to protein dysfunction and therefore contribute to disease pathogenesis.

Discussion

FCAS is a dominantly inherited disease with the recurrent symptoms of early onset and lifelong urticarial-like rashes after exposure to cold environments. Clinical symptoms are mild and

Table 2. Summary of the Exome Sequencing Data.

| Sample | Clean_data (Gb) | Aligned (%) | Initial bases on target (Mb) | Base covered on target (Mb) | Effective bases on target (%) | Base covered on target (%) | Base covered on target (%) | 10× coverage (%) | 10× coverage (%) | 20× coverage (%) |
|--------|----------------|-------------|-------------------------------|--------------------------|-------------------------------|--------------------------|----------------------------|-----------------|-----------------|-----------------|
| II-4   | 5.43           | 99.20       | 50.34                         | 49.08                    | 57.00                         | 55.39                    | 95.70                      | 91.80           | 82.70           |
| II-5   | 5.19           | 99.70       | 50.34                         | 49.05                    | 60.00                         | 56.51                    | 95.80                      | 92.00           | 83.10           |
| III-3  | 6.24           | 98.70       | 50.34                         | 49.47                    | 49.30                         | 58.85                    | 96.70                      | 93.50           | 84.70           |
| III-4  | 6.58           | 99.10       | 50.34                         | 49.13                    | 55.40                         | 64.64                    | 96.20                      | 93.00           | 85.00           |
| IV-1   | 6.86           | 98.40       | 50.34                         | 49.02                    | 57.40                         | 69.82                    | 95.60                      | 91.80           | 83.80           |
| IV-2   | 5.09           | 99.70       | 50.34                         | 49.21                    | 52.90                         | 51.65                    | 96.20                      | 92.10           | 81.30           |
| Mean   | 5.90           | 99.13       | 50.34                         | 49.16                    | 55.33                         | 59.48                    | 96.03                      | 92.37           | 83.43           |
| STDEV  | 0.69           | 0.48        | 0.00                          | 0.15                     | 3.44                          | 6.07                     | 0.38                       | 0.65            | 1.25            |

doi:10.1371/journal.pone.0156981.t002

PLOS ONE | DOI:10.1371/journal.pone.0156981 June 17, 2016 6 / 12
include rashes, polyarthragia and fever. These symptoms occasionally overlap with symptoms of CAPS, MWS and CINCA/NOMID [13]. FCAS is an extremely rare syndrome and is not a well-recognized disease. Therefore, we speculate that many more cases may still be undiagnosed or even misdiagnosed. The familial history of this disease indicates that genetic factors may play an important role in disease development.

FCAS has shown distinct genetic heterogeneity, which suggests that the disease may be caused by mutations in more than one gene. Therefore, we sought to investigate whether additional disease genes besides those previously reported could lead to FCAS. WES has shown great promise as a powerful tool for understanding the genetic architecture of human disease as well as in diagnostic procedures. Through exome sequencing techniques, the underlying genetic cause of some diseases has been discovered [14, 19, 20]. In addition, with the rapid development of next-generation sequencing techniques, the cost of exome sequencing has drastically decreased. Therefore, in this study, we directly employed exome sequencing to investigate the inherited genetic defect in a FCAS family. One reason we did not directly use PCR and Sanger sequencing is that it is expensive to perform these procedures on all four known FCAS genes. Another reason is that it is often difficult and time-consuming to amplify all the exonic regions using PCR. Our results demonstrated that exome sequencing can replace PCR and Sanger sequencing and can be used as a genetic diagnostic tool for larger pedigrees in the future.

Fig 3. Structural Difference between Wild-type and C-terminal Truncated NLRP12 Proteins. Function predictions of the truncated protein and the wild-type (full-length) NLRP12 were carried out. The truncated protein (p.Trp408X) is represented in green. The full length protein is represented in blue. It is clear that the mutation disrupts the integrity of the NLRP12 protein.

doi:10.1371/journal.pone.0156981.g003
In this study, we employed a commonly used protocol for exome sequencing data analysis. First, BWA and GATK software were used for the detection of mutations from sequencing data. Second, we took advantage of in-house exome databases and several public databases as normal controls. In our study, we used this protocol to successfully identify a pathogenic mutation in a family with FCAS, which illustrated the effectiveness of exome sequencing technology for the identification of disease-causing genes for an extremely rare disease. We acknowledge one report that used exome sequencing to identify the mutation in \textit{NLRP12} for common variable immunodeficiency disease [21].

According to the literature, \textit{NLRP12} has six causative mutations linked to FCAS, including the present mutation. These mutations and their corresponding clinical characteristics are summarized in Table 3 [13, 21–26]. Surprisingly, we found that all of the reported mutations were located in exon 3 and intron 3 (the flanking sequence of exon 3) of \textit{NLRP12}. This finding indicates that this region of \textit{NLRP12} may be a mutational hotspot in FCAS and highlights that more attention should be paid to this region when screening for mutations in FCAS. Furthermore, we provide insights into the clinically heterogeneous nature of FCAS because, even when mutations are encoded within the same exon, the clinical manifestations are dramatically different (Table 3). Specifically, episodic fever, arthralgia, myalgia, and urticaria could be triggered by cold exposure in individuals carrying the p.R284X mutation in \textit{NLRP12}. Recurrent bouts of fever and severe fatigue (musculo-skeletal symptoms) have been observed in patients carrying the p.F402L mutation in \textit{NLRP12}. Notably, the p.R284X mutation in \textit{NLRP12} may be linked to sensorineural hearing loss.

We also mapped all the reported mutations in \textit{NLRP12}, \textit{NLRP3}, \textit{NLRC4} and \textit{PLCG2} (Fig 4), which are the four genes linked with FCAS. With the exception of \textit{PLCG2}, almost all of the reported mutations were located at a highly conserved region in the NACHT domain, which demonstrates that this domain is the key functional region of the \textit{NLRP} gene family in the context of FCAS. As such, NACHT is a key region in the clinical molecular diagnosis of FCAS and should be prioritized for sequencing. The NACHT domain is closely related to the nucleotide-binding adaptor NB-ARC, which is shared by apoptotic ATPases, such as the apoptotic protease activating factor-1 (APAF1), NLR family CARD domain-containing proteins (NLRC4), plant resistance (R), and Caenorhabditis elegans cell death (CED-4) proteins [28]. Proteins containing these domains are considered to be regulators of programmed cell death in animals.

| Mutation | Location | Phenotype | Autosomal dominant | Esp$6500$ Allele freq | 1000G Allele freq | ExACA Allele freq | References |
|----------|----------|-----------|--------------------|-----------------------|--------------------|--------------------|-------------|
| c.850C>T, p.R284X | Exon3 | Onset at first days of life; Episodic fever, arthralgia, myalgia, and urticaria by cold; sensorineural hearing loss. | Yes | 7.690 e-04 | 2.396 e-03 | 2.277e-04 | [7, 27] |
| c.882C>G, p.D294E | Exon3 | Onset at child; Cold-induced urticarial rash, arthralgias and myalgia; Elevation of acute-phase reactants | Yes | ND | ND | 8.132e-06 | [13] |
| c.910C>T, p.H304Y | Exon3 | Classical FCAS2 clinical manifestation | NA | 2.691 e-03 | 2.196 e-03 | 4.220e-03 | [26] |
| c.1223G>A p. W408X | Exon3 | Onset at first year of life Episodic fever, urticaria and arthralgia triggered by cold | Yes | ND | ND | ND | In this study |
| c.1206C>G, p.F402L | Exon3 | Recurrent fever, skin rashes, abdominal pain and tonsillitis; Good response to IL-1 inhibitor; | Yes/NA | 5.113 e-02 | 2.696 e-02 | 5.200 e-02 | [22, 23] |
| c.2072+3insT, p. Val635ThrfsX12 | Intron3 | Onset at first year; Episodic fever, abdominal pain and arthralgia triggered by cold. | Yes | ND | ND | ND | [7] |

Table 3. \textit{NLRP12} Gene Mutations and Diseases. ND, Not detectable; NA, No answer.

doi:10.1371/journal.pone.0156981.t003
Novel Mutation of NLRP12 in FCAS

Fig 4. Schematic Diagram of Mutations in the Encoded Proteins of NLRP12/NLRP3/NLRC4/PLCG2 Genes Associated with FCAS. Rectangles with different colors indicate specific protein domains. The solid blue line indicates the position of the reported mutation, and the solid red line shows the p.Trp408* mutation related to our study.

doi:10.1371/journal.pone.0156981.g004
and plants via an ATP-dependent protein oligomerization process. To date, no NACHT domain crystal structure has been published for any NLRP family member. Although the contributions of the NACHT domain to the specific biological functions of the various NLRP genes are unknown, it is proposed that the central NACHT nucleotide-binding domain of the NLRP family offers a novel opportunity for pharmacologic intervention [28].

NLRP12 encodes a member of the CATERPILLER family of cytoplasmic proteins, which function as important components of inflammation and immunity [29]. Human NLRP12 is expressed by monocytes/macrophages and granulocytes and is a regulator of NF-κB activation, where it acts as a negative controller of inflammation, suppressing both canonical and non-canonical NF-κB activation [27, 30]. In the absence or mutation of NLRP12, biosynthesis of cytokines including IL-1 is increased. The weak clinical symptoms of FCAS are, therefore, likely due to the accelerated kinetics of IL-1 secretion in the absence of an overall increased amount of the secreted cytokine [13]. The molecular consequences of several mutations have been studied. In vitro functional expression studies have shown that the mutations (p.R284X and 2072+3insT) in NLRP12, which have a similar phenotype in patients (Table 3), had reduced inhibitory action against NF-κB compared to wild-type NLRP12. A dominant mode of expression through haploinsufficiency was suggested [7]. We speculate that a similar molecular consequence may be present, as observed with the p.Trp408X mutation. Further studies are required to elucidate the detailed molecular consequences of this mutation.

To the best of our knowledge, this is the first case to report a novel disease-causing mutation (p.Trp408X) in NLRP12 for autosomal dominant inherited FCAS. We suggest that the screening strategy for FCAS should be targeted to gene fragments coding for the key region (the NACHT domain encoded by exon 3). In addition, this study provides further molecular insight for FCAS treatment and diagnosis, as well as illustrating the important role of exome sequencing in the clinical diagnosis of genetic disorders.

Supporting Information

S1 Table. The list of 13 SNVs and 2 Indels corresponding to Fig 2A.

(DOCX)

Acknowledgments

We thank the family and all subjects for taking part in this project. We are indebted to Dr. Jinyu Wu, Dr. Feng Gu (Institute of Genomic Medicine, School of Ophthalmology and Optometry, Wenzhou Medical University), and Dr. Yuan Liu, Peking University (Center for Life Science, Academy for Advanced Interdisciplinary Studies, Peking University).

Author Contributions

Conceived and designed the experiments: LW. Performed the experiments: XX CD. Analyzed the data: XX CD XL YF. Contributed reagents/materials/analysis tools: XX CD XL YF. Wrote the paper: XX LW.

References

1. Cuisset L, Jeru I, Dumont B, Fabre A, Cochet E, Le Bozec J, et al. Mutations in the autoinflammatory-cryopyrin-associated periodic syndrome gene: epidemiological study and lessons from eight years of genetic analysis in France. Ann Rheum Dis. 2011; 70: 495–499. doi:10.1136/ard.2010.139420 PMID: 21109514

2. Kapur S, Bonk ME. Rilonacept (Arcalyst), an interleukin-1 trap for the treatment of cryopyrin-associated periodic syndromes. P T. 2009; 34: 138–141. PMID: 19561849
3. de Jesus AA, Goldbach-Mansky R. Monogenic autoinflammatory diseases: concept and clinical manifestations. ClinImmunol. 2013; 147: 155–174.
4. Ida H. Pathogenesis and clinical examination of autoinflammatory syndrome. RinshoByori. 2015; 63: 1207–1212.
5. Hoffmann HM, Wanderer AA, Broide DH. Familial cold autoinflammatory syndrome: phenotype and genotype of an autosomal dominant periodic fever. J Allergy ClinImmunol. 2001; 108: 615–620.
6. Kitamura A, Sasaki Y, Abe T, Kano H, Yasutomo K. An inherited mutation in NLRC4 causes autoinflammation in human and mice. J Exper Med. 2014; 211: 2385–2396.
7. Jurj I, Duquesnoy P, Fernandes-Alnemri T, Cochet E, Yu JW, Lackmy-Port-Lis M, et al. Mutations in NALP12 cause hereditary periodic fever syndromes. Proc Natl AcadSci U S A. 2008; 105: 1614–1619.
8. Tunca M, Ozdogan H. Molecular and genetic characteristics of hereditary autoinflammatory diseases. Curr Drug Targets Inflamm Allergy. 2005; 4: 77–80. PMID: 15720239
9. Hoffmann HM, Gregory SG, Mueller JL, Tresierras M, Broide DH, Wanderer AA, et al. Fine structure mapping of CIAS1: identification of an ancestral haplotype and a new FCAS mutation, L353P. Hum Genet. 2003; 112: 209–216. PMID: 12622564
10. Shinar Y, Obici L, Aksentijevich I, Bennetts B, Austrup F, Ceccherini I, et al. Guidelines for the genetic diagnosis of hereditary recurrent fevers. Ann Rheum Dis. 2012; 71: 1599–1605. doi: 10.1136/annrheumdis-2011-201271 PMID: 22661645
11. Aksentijevich I, Putnam CD, Remmers EF, Mueller JL, Le J, Kolodner RD, et al. The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis Rheum. 2007; 56: 1273–1285. PMID: 17393462
12. Ombrello MJ, Remmers EF, Sun G, Freeman AF, Datta S, Torabi-Parizi P, et al. Cold urticaria, immunodeficiency, and autoimmunity related to PLCG2 deletions. New Eng J Med 2012; 366: 330–338. doi: 10.1056/NEJMoa1102140 PMID: 22236196
13. Borghini S, Tassi S, Chiesa S, Caroli F, Carta S, Caorsi R, et al. Clinical presentation and pathogenesis of cold-induced autoinflammatory disease in a family with recurrence of an NLRP12 mutation. Arthritis Rheum. 2011; 63: 830–839. doi: 10.1002/art.30170 PMID: 21360512
14. Rabbani B, Mahdieh N, Hosomichi K, Nakaoka H, Inoue I. Next-generation sequencing: impact of exome sequencing in characterizing Mendelian disorders. J Hum Genet. 2012; 57: 621–632. doi: 10.1038/jhg.2012.91 PMID: 22832387
15. Cai T, Yang L, Cai W, Guo S, Yu P, Li J, et al. Dysplastic spondylolysis is caused by mutations in the diastrophic dysplasia sulfate transporter gene. Proc Natl AcadSci U S A. 2015; 112: 8064–8069.
16. Crucenceau C, Ambalavanan A, Spiegelman D, Gauthier J, Lafreniere RG, Dion PA, et al. Family-based exome-sequencing approach identifies rare susceptibility variants for lithium-responsive bipolar disorder. Genome. 2013; 56: 634–640. doi: 10.1136/gen-2013-0081 PMID: 24237345
17. Li G, Yu J, Wang K, Wang B, Wang M, Zhang S, et al. Exome sequencing identified new mutations in a Marfan syndrome family. DiagnPathol. 2014; 9: 25.
18. Li J, Jiang Y, Wang T, Chen H, Xie Q, Shao Q, et al. mirTrios: an integrated pipeline for detection of de novo and rare inherited mutations from trios-based next-generation sequencing. J Med Genet. 2015; 52: 275–281. doi: 10.1136/jmedgenet-2014-102656 PMID: 25996308
19. Goh G, Choi M. Application of whole exome sequencing to identify disease-causing variants in inherited human diseases. Genomics Inform. 2012; 10: 214–219. doi: 10.5808/GI.2012.10.4.214 PMID: 23946032
20. Barmshad MJ, Ng SB, Bigham AW, Tabor HK, Emond MJ, Nickerson DA, et al. Exome sequencing as a tool for Mendelian disease gene discovery, Nat Rev Genet. 2011; 12: 745–755. doi: 10.1038/nrg3031 PMID: 21946919
21. Borte S, Celiksoy MH, Menzel V, Ozkaya O, Ozen FZ, Hammarstrom L, et al. Novel NLRP12 mutations associated with intestinal amyloidosis in a patient diagnosed with common variable immunodeficiency. ClinImmunol. 2014; 154: 105–111.
22. Vitale A, Rigante D, Maggio MC, Emmi G, Romano M, Silvestri E, et al. Rare NLRP12 variants associated with the NLRP12-autoinflammatory disorder phenotype: an Italian case series. ClinExpRheumatol. 2013; 31: 155–156.
23. De Pieri C, Vuch J, Athanasakis E, Severini GM, Crovella S, Bianco AM, et al. F402L variant in NLRP12 in subjects with undiagnosed periodic fevers and in healthy controls. ClinExpRheumatol. 2014; 32: 993–994.
24. Vitale A, Rigante D, Lucherini OM, Caso F, Cantarini L. The role of the F402L allele in the NLRP12-autoinflammatory disorder. Reply to: F402L variant in NLRP12 in subjects with undiagnosed periodic fevers and in healthy controls, De Pieri et al. ClinExpRheumatol. 2014; 32: 994.
25. De Pieri C, Vuch J, De Martino E, Bianco AM, Ronfani L, Athanasakis E, et al. Genetic profiling of auto-inflammatory disorders in patients with periodic fever: a prospective study. Pediatr Rheumatol Online J. 2015; 13: 11.

26. Rusmini M, Federici S, Caroli F, Grossi A, Baldi M, Obici L, et al. Next-generation sequencing and its initial applications for molecular diagnosis of systemic auto-inflammatory diseases. Ann Rheum Dis. 2015. doi: 10.1136/annrheumdis-2015-207701

27. Jeru I, Hentgen V, Normand S, Duquesnoy P, Cochet E, Delwail A, et al. Role of interleukin-1beta in NLRP12-associated autoinflammatory disorders and resistance to anti-interleukin-1 therapy. Arthritis Rheum. 2011; 63: 2142–2148. doi: 10.1002/art.30378 PMID: 21480187

28. MacDonald JA, Wijekoon CP, Liao K-C, Muruve DA. Biochemical and structural aspects of the ATP-binding domain in inflammasome-forming human NLRP proteins. IUBMB Life. 2013; 65: 851–862. doi: 10.1002/iub.1210 PMID: 24078393

29. Arthur JC, Lich JD, Ye Z, Allen IC, Gris D, Wilson JE, et al. Cutting edge: NLRP12 controls dendritic and myeloid cell migration to affect contact hypersensitivity. J Immunol. 2010; 185: 4515–4519. doi: 10.4049/jimmunol.1002227 PMID: 20861349

30. Lich JD, Williams KL, Moore CB, Arthur JC, Davis BK, Taxman DJ, et al. Monarch-1 suppresses non-canonical NF-kappaB activation and p52-dependent chemokine expression in monocytes. J Immunol. 2007; 178: 1256–1260. PMID: 17237370